Clinical Trial Update: Trial to Evaluate Safety and Immunogenicity of a Vaccine Against HCMV [Phase 1]

View source ↗

Summary

Phase 1 trial assessing safety and immunogenicity of an HCMV vaccine by Hookipa Biotech has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• HCMV vaccine

Snippet

Sponsor: Hookipa Biotech GmbH | Conditions: Cytomegalovirus Infection | Phase 1 | Status: COMPLETED